By Ted Slafsky

By the first week of June, we should have a better sense of how the Trump administration plans to address the drug industry’s desire to impose a rebate model rather than the longstanding upfront discount that the government has allowed since Congress established the 340B program in 1992.

On May 2, lawyers for the U.S. Department of Health and Human Services (HHS) told a U.S. district court in Washington, D.C. that it would release guidance within 30 days on 340B rebate models and how they may interact with the Inflation Reduction Act’s (IRA) Medicare drug price negotiations. Read More >